艾伯多米德,艾克萨佐米布和德克萨米松在老年患者多发性骨髓瘤在第一次复发时
Cyrille Touzeau1,2,3, Xavier Leleu4, Mourad Tiab5
1Service d'hématologie, Centre Hospitalo-Universitaire, Nantes, France.
British journal of haematology
|January 6, 2025
概括
I2D研究表明,口服三重剂伊贝尔多米德,伊克萨佐米布和德克萨米松在首次复发时对老年多发性骨髓瘤 (MM) 患者有效. 这种治疗提供了有利的风险-益处概况,即使对于那些对莱纳利多米德或达拉图穆马布耐药的人来说也是如此.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 复发性多发性骨髓瘤 (MM) 的老年患者往往对标准疗法如利那利多米德和抗CD38单克隆抗体具有耐药性.
- 这一群体代表着对有效和可容忍的治疗选择的重大未满足需求.
研究的目的:
- 评价Iberdomide,Ixazomib和Dexamethasone (I2D) 的口服三重剂疗法的疗效和安全性,用于在第一次复发时患有多发性骨髓瘤的移植不合格患者.
主要方法:
- 一项第二阶段研究 (NCT04998786) 招募了70名老年患者 (≥70岁) 患有复发性MM.
- 患者在28天的循环中接受口服伊贝尔多米德,伊克萨佐米布和德克萨梅他,直到疾病进展.
- 关键的终点包括整体反应率 (ORR),无进展生存率 (PFS),反应持续时间 (DoR) 和整体生存率 (OS).
主要成果:
- 整体反应率 (ORR) 为64%,其中36%的患者获得了非常好的部分反应或更好.
- 随访时间中位数为14个月,12个月的PFS,DoR和OS率分别为52%,76%和86%.
- 最常见的3-4级毒性是中性质减退 (46%);其他不良事件主要是1级或2级.
结论:
- I2D口服三倍剂在复发多发性骨髓瘤的老年患者中显示出有利的风险-益处概况.
- 这种疗法对难以治疗的患者有希望,包括那些对莱纳利多米德和达拉图穆马布耐药的患者.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
174
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
174
Inflammatory Bowel Disease IV: Pharmacological Management
110
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
110
Drugs for Treatment of Diarrhea-Predominant IBS
146
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
146
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
219
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
219


